Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anti-BCMA CAR T-Cells in Previously Treated Multiple Myeloma
NCT02215967Phase 1Completed
- Sponsor
- National Cancer Institute
- Start
- Aug 2014
- Primary completion
- Apr 2019
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial in multiple myeloma (MM), sponsored by National Cancer Institute. Primary endpoints: Dose Limiting Toxicities at 60 days and Serious and Non-serious Adverse Events up to 48 months. Started Aug 2014; status: completed.
02
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT02215967.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02215967.